Ultimately, translating these cues into in vivo models and clinical samples of osimertinib resistant EGFR-mutant NSCLC patients will be instrumental in validating novel targets that can potentially have a strong therapeutic index in clinical settings. Here, EGFR is linked to non-small cell lung carcinoma.